{"count":6,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/3fd8b296-e504-4946-9d39-fde5ba084aa0/","filing_uuid":"3fd8b296-e504-4946-9d39-fde5ba084aa0","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/3fd8b296-e504-4946-9d39-fde5ba084aa0/print/","filing_document_content_type":"text/html","income":null,"expenses":"210000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"8r1","dt_posted":"2026-04-15T11:09:05-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2318 Mill Rd","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"Alexandria","registrant_state":"VA","registrant_zip":"22314","registrant":{"id":401105592,"url":"https://lda.gov/api/v1/registrants/401105592/","house_registrant_id":null,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","description":"physician medical specialty society","address_1":"2318 Mill Rd","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Alexandria","state":"VA","state_display":"Virginia","zip":"22314","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANTHONY PEREZ","contact_telephone":"+1 571-483-1496","dt_updated":"2026-07-21T14:12:19.395401-04:00"},"client":{"id":205751,"url":"https://lda.gov/api/v1/clients/205751/","client_id":12,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"VA","state_display":"Virginia","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. H.R. 1509/S. 752: Accelerating Kids Access to Care Act - To amend titles XIX and XXI of the Social Security Act to streamline the enrollment process for eligible out-of-state providers under Medicaid and CHIP. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation. H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Mikaela Naylon Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY 2026 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP). FY 2027 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d48a3371-625d-45d4-a725-d1e8ea0d7d00/","filing_uuid":"d48a3371-625d-45d4-a725-d1e8ea0d7d00","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d48a3371-625d-45d4-a725-d1e8ea0d7d00/print/","filing_document_content_type":"text/html","income":null,"expenses":"480000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"Kristine Rufener","dt_posted":"2026-07-16T11:38:53-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2318 Mill Rd","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"Alexandria","registrant_state":"VA","registrant_zip":"22314","registrant":{"id":401105592,"url":"https://lda.gov/api/v1/registrants/401105592/","house_registrant_id":null,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","description":"physician medical specialty society","address_1":"2318 Mill Rd","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Alexandria","state":"VA","state_display":"Virginia","zip":"22314","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANTHONY PEREZ","contact_telephone":"+1 571-483-1496","dt_updated":"2026-07-21T14:12:19.395401-04:00"},"client":{"id":205751,"url":"https://lda.gov/api/v1/clients/205751/","client_id":12,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"VA","state_display":"Virginia","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. H.R. 8163: Provider Reimbursement Stability Act, to amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program. H.R. 8622: Medicare Physician Data-driven Performance Payment System Act to amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-driven Performance Payment System under the Medicare physician fee schedule H.R. 6160: Strengthening Medicare for Patients and Providers Act to modify certain adjustments to payment amounts under the Medicare physician fee schedule S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY 2026 and FY 2027 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/f4b0b8bc-7c0e-4ca9-b780-eaf54b336c73/","filing_uuid":"f4b0b8bc-7c0e-4ca9-b780-eaf54b336c73","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/f4b0b8bc-7c0e-4ca9-b780-eaf54b336c73/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Katina Pierce","dt_posted":"2026-07-17T13:17:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"600 Maryland Avenue SW","registrant_address_2":"Suite 220E","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":8511,"url":"https://lda.gov/api/v1/registrants/8511/","house_registrant_id":31321,"name":"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.","description":"Consultant firm","address_1":"600 Maryland Avenue SW","address_2":"Suite 220E","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATINA PIERCE","contact_telephone":"+1 202-484-1100","dt_updated":"2026-07-07T12:11:18.019485-04:00"},"client":{"id":209711,"url":"https://lda.gov/api/v1/clients/209711/","client_id":1005383,"name":"HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION","general_description":"Supports pharmacy practitioners & seeks to promote & advance hematology/oncology pharmacy","client_government_entity":false,"client_self_select":null,"state":"WI","state_display":"Wisconsin","country":"US","country_display":"United States of America","ppb_state":"WI","ppb_state_display":"Wisconsin","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY27 Labor Health Human Services and Related Agencies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":98793,"prefix":null,"prefix_display":null,"first_name":"JEREMY","nickname":null,"middle_name":null,"last_name":"SCOTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69553,"prefix":null,"prefix_display":null,"first_name":"STEFANIE","nickname":null,"middle_name":"CLAUDETTE WINSTON","last_name":"RINEHART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148303,"prefix":null,"prefix_display":null,"first_name":"KELSI","nickname":null,"middle_name":null,"last_name":"PUTNAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Safe Step Act (H.R. 5509 / S. 2903); Cancer Drug Parity Act (H.R. 4101)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":98793,"prefix":null,"prefix_display":null,"first_name":"JEREMY","nickname":null,"middle_name":null,"last_name":"SCOTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154339,"prefix":null,"prefix_display":null,"first_name":"STEFANI","nickname":null,"middle_name":null,"last_name":"RINEHART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/81a9cfc0-3c6e-49a8-9e78-a6caddf6f18b/","filing_uuid":"81a9cfc0-3c6e-49a8-9e78-a6caddf6f18b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/81a9cfc0-3c6e-49a8-9e78-a6caddf6f18b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Katina Pierce","dt_posted":"2026-10-07T08:14:38-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"600 Maryland Avenue SW","registrant_address_2":"Suite 220E","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":8511,"url":"https://lda.gov/api/v1/registrants/8511/","house_registrant_id":31321,"name":"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.","description":"Consultant firm","address_1":"600 Maryland Avenue SW","address_2":"Suite 220E","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATINA PIERCE","contact_telephone":"+1 202-484-1100","dt_updated":"2026-07-07T12:11:18.019485-04:00"},"client":{"id":209711,"url":"https://lda.gov/api/v1/clients/209711/","client_id":1005383,"name":"HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION","general_description":"Supports pharmacy practitioners & seeks to promote & advance hematology/oncology pharmacy","client_government_entity":false,"client_self_select":null,"state":"WI","state_display":"Wisconsin","country":"US","country_display":"United States of America","ppb_state":"WI","ppb_state_display":"Wisconsin","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY27 Labor Health Human Services and Related Agencies; Continuing Resolution","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":98793,"prefix":null,"prefix_display":null,"first_name":"JEREMY","nickname":null,"middle_name":null,"last_name":"SCOTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154339,"prefix":null,"prefix_display":null,"first_name":"STEFANI","nickname":null,"middle_name":null,"last_name":"RINEHART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148303,"prefix":null,"prefix_display":null,"first_name":"KELSI","nickname":null,"middle_name":null,"last_name":"PUTNAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Cancer Drug Parity Act (H.R. 4101 / S. 5004); Improving Seniors' Timely Access to Care Act (H.R. 3514 / S. 1816); Drug Shortages","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":98793,"prefix":null,"prefix_display":null,"first_name":"JEREMY","nickname":null,"middle_name":null,"last_name":"SCOTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154339,"prefix":null,"prefix_display":null,"first_name":"STEFANI","nickname":null,"middle_name":null,"last_name":"RINEHART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148303,"prefix":null,"prefix_display":null,"first_name":"KELSI","nickname":null,"middle_name":null,"last_name":"PUTNAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/09aa0bfb-1c0d-47c2-93c3-35b4085c10af/","filing_uuid":"09aa0bfb-1c0d-47c2-93c3-35b4085c10af","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/09aa0bfb-1c0d-47c2-93c3-35b4085c10af/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"Kristine Rufener","dt_posted":"2026-10-15T11:15:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2318 Mill Rd","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"Alexandria","registrant_state":"VA","registrant_zip":"22314","registrant":{"id":401105592,"url":"https://lda.gov/api/v1/registrants/401105592/","house_registrant_id":null,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","description":"physician medical specialty society","address_1":"2318 Mill Rd","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Alexandria","state":"VA","state_display":"Virginia","zip":"22314","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANTHONY PEREZ","contact_telephone":"+1 571-483-1496","dt_updated":"2026-07-21T14:12:19.395401-04:00"},"client":{"id":205751,"url":"https://lda.gov/api/v1/clients/205751/","client_id":12,"name":"ASSOCIATION FOR CLINICAL ONCOLOGY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"VA","state_display":"Virginia","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. H.R. 9693, Patients First Act of 2026 would finally make structural changes needed to prevent cuts and create a payment system that helps ensure physicians can keep their doors open and provide seniors with quality, value-based healthcare. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. H.R. 8163/S. 5180: Provider Reimbursement Stability Act, to amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program. H.R. 8622: Medicare Physician Data-driven Performance Payment System Act to amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-driven Performance Payment System under the Medicare physician fee schedule H.R. 6160: Strengthening Medicare for Patients and Providers Act to modify certain adjustments to payment amounts under the Medicare physician fee schedule S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation. H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation. H.R. 8500: Timely Access to Coverage Decisions Act of 2026: To amend title XVIII of the Social Security Act to ensure timely review of local coverage determination requests under the Medicare program. H.R. 4331, Access to Claims Data Act: To require the Secretary of Health and Human Services to establish a process to expand access to claims data under certain Federal health plans in order to facilitate research and quality improvement.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839/S. 5052: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY 2027 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). Appropriations for the Dr. Lorna Breen Health Care Provider Protection Act for FY27.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":120202,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"RUFENER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141122,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"GIFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154875,"prefix":"ms","prefix_display":"MS.","first_name":"MAUREEN","nickname":null,"middle_name":"ELIZABETH","last_name":"SZEMBORSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/","filing_uuid":"cb8d32e9-83d7-48be-b71a-d96e2736dd8d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/print/","filing_document_content_type":"text/html","income":null,"expenses":"3600000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-10-20T14:54:17-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1275 Pennsylvania Avenue, NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":31326,"url":"https://lda.gov/api/v1/registrants/31326/","house_registrant_id":31354,"name":"PFIZER INC.","description":"Biopharmaceuticals","address_1":"1275 Pennsylvania Avenue, NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-08-21T13:00:31.079287-04:00"},"client":{"id":138225,"url":"https://lda.gov/api/v1/clients/138225/","client_id":12,"name":"PFIZER INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72512,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"CLAEYS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69774,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}